Home Featured Page 108

Featured

Latest

Breaking: U.S. Government Taps Mark Cuban’s Company to Develop Ibogaine for PTSD; Commits to Fund $20M Real-World Evidence Network

220 Patients or 20,000? Clinics Split on Psychedelics’ First Year

Robert Rush: Emergency Scheduling, 7-OH, and the War on Research

Breaking: Compass Files Psilocybin for TRD New Drug Application with FDA

The Problems We Will Be Lucky to Have

Psychedelic Research Bulletin: June 2023

PT421 – The Impact of the Therapeutic Alliance on the Psychedelic...

FILAMENT HEALTH TO SUPPLY PSILOCYBIN FOR RECIPIENTS OF THE CANADIAN INSTITUTES...

COMPASS Pathways Secures Term Loan Facility for Up to $50 Million...

Small Pharma Announces SPL028 R&D Strategy Update

Wesana Health Announces Closing of Previously Announced SANA-013 Asset Sale

Into the Psychedelic Practitioner Toolbox: Using a Transpersonal Approach

PT420 – DanceSafe: Drug Testing, Fentanyl Myths, and the Importance of...

Psychedelic Summer Safety: The Ultimate Guide to Making the Most Out...

Psychedelics Weekly – A Recap of Psychedelic Science 2023

EDITOR PICKS

Breaking: U.S. Government Taps Mark Cuban’s Company to Develop Ibogaine for...

220 Patients or 20,000? Clinics Split on Psychedelics’ First Year

Robert Rush: Emergency Scheduling, 7-OH, and the War on Research

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Breaking: U.S. Government Taps Mark Cuban’s Company to Develop Ibogaine for PTSD; Commits to Fund $20M Real-World Evidence Network

220 Patients or 20,000? Clinics Split on Psychedelics’ First Year

Robert Rush: Emergency Scheduling, 7-OH, and the War on Research

Breaking: Compass Files Psilocybin for TRD New Drug Application with FDA

The Problems We Will Be Lucky to Have

Psychedelic Research Bulletin: June 2023

PT421 – The Impact of the Therapeutic Alliance on the Psychedelic...

FILAMENT HEALTH TO SUPPLY PSILOCYBIN FOR RECIPIENTS OF THE CANADIAN INSTITUTES...

COMPASS Pathways Secures Term Loan Facility for Up to $50 Million...

Small Pharma Announces SPL028 R&D Strategy Update

Wesana Health Announces Closing of Previously Announced SANA-013 Asset Sale

Into the Psychedelic Practitioner Toolbox: Using a Transpersonal Approach

PT420 – DanceSafe: Drug Testing, Fentanyl Myths, and the Importance of...

Psychedelic Summer Safety: The Ultimate Guide to Making the Most Out...

Psychedelics Weekly – A Recap of Psychedelic Science 2023

EDITOR PICKS

Breaking: U.S. Government Taps Mark Cuban’s Company to Develop Ibogaine for...

220 Patients or 20,000? Clinics Split on Psychedelics’ First Year

Robert Rush: Emergency Scheduling, 7-OH, and the War on Research

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY